Jump to navigation Jump to search
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||104809.42 g·mol−1|
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)
- Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
- "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.